Hikma Buys Teligent’s Canadian Assets
The UK’s Hikma Pharmaceuticals has agreed to pay $45.75 million for the Canadian business of Teligent, a US generic drugmaker that filed for Chapter 11 bankruptcy protection in October 2021 and initiated a sale of its core assets. The deal is expected to close before the end of the first quarter of 2022.
